Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

M. S. Zabriskie; C. A. Eide; D. Yan; N. A. Vellore; A. D. Pomicter; S. L. Savage; B. J. Druker; M. W. Deininger; T. O'Hare

doi:10.1038/leu.2015.318

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

M. S. Zabriskie, C. A. Eide, D. Yan, N. A. Vellore, A. D. Pomicter, S. L. Savage, B. J. Druker, M. W. Deininger, T. O'Hare

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	1418-1421
Number of pages	4
Journal	Leukemia
Volume	30
Issue number	6
DOIs	https://doi.org/10.1038/leu.2015.318
State	Published - Jun 1 2016

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2015.318

Cite this

@article{537d279637a04ff3805694e5915c87cf,

title = "Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia",

author = "Zabriskie, {M. S.} and Eide, {C. A.} and D. Yan and Vellore, {N. A.} and Pomicter, {A. D.} and Savage, {S. L.} and Druker, {B. J.} and Deininger, {M. W.} and T. O'Hare",

note = "Funding Information: Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health under Award Numbers R01CA178397 (MWD and TO) and P01 CA049639 (MWD), and by a Specialized Center of Research Program Award (SCOR7005 11) from The Leukemia & Lymphoma Society (MWD). We acknowledge support in conjunction with grant P30 CA042014 awarded to the Huntsman Cancer Institute (MWD and TO). BJD is a Howard Hughes Medical Institute investigator and supported by NCI MERIT award R37CA065823. We thank Severine Bateman, a University of Utah ACCESS Program for Women in Science & Mathematics scholar, for technical assistance. Funding Information: Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health under Award Numbers R01CA178397 (MWD and TO) and P01 CA049639 (MWD), and by a Specialized Center of Research Program.",

year = "2016",

month = jun,

day = "1",

doi = "10.1038/leu.2015.318",

language = "English (US)",

volume = "30",

pages = "1418--1421",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

AU - Zabriskie, M. S.

AU - Eide, C. A.

AU - Yan, D.

AU - Vellore, N. A.

AU - Pomicter, A. D.

AU - Savage, S. L.

AU - Druker, B. J.

AU - Deininger, M. W.

AU - O'Hare, T.

N1 - Funding Information: Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health under Award Numbers R01CA178397 (MWD and TO) and P01 CA049639 (MWD), and by a Specialized Center of Research Program Award (SCOR7005 11) from The Leukemia & Lymphoma Society (MWD). We acknowledge support in conjunction with grant P30 CA042014 awarded to the Huntsman Cancer Institute (MWD and TO). BJD is a Howard Hughes Medical Institute investigator and supported by NCI MERIT award R37CA065823. We thank Severine Bateman, a University of Utah ACCESS Program for Women in Science & Mathematics scholar, for technical assistance. Funding Information: Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health under Award Numbers R01CA178397 (MWD and TO) and P01 CA049639 (MWD), and by a Specialized Center of Research Program.

PY - 2016/6/1

Y1 - 2016/6/1

UR - http://www.scopus.com/inward/record.url?scp=84949256311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949256311&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.318

DO - 10.1038/leu.2015.318

M3 - Letter

C2 - 26582647

AN - SCOPUS:84949256311

SN - 0887-6924

VL - 30

SP - 1418

EP - 1421

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this